Asthma treatment outcome in adults is associated with rs9910408 in TBX21 gene

Lopert, Anton; Rijavec, Matija; Žavbi, Mateja; Korošec, Peter; Fležar, Matjaž
October 2013
Scientific Reports;10/10/2013, p1
Academic Journal
Inhaled corticosteroids (ICS) are one of the most commonly used asthma therapies and have highly variable treatment success. Polymorphisms in TBX21, a gene important for the biological action of corticosteroids, could be associated with treatment response in asthmatics. We genotyped for rs9910408 in TBX21 in 208 adult asthmatic patients, treated at least 3 years with ICS. Polymorphism rs9910408 was associated with response to ICS treatment. When treatment success was assessed by a decrease in bronchial hyperresponsiveness (BHR), the frequency ofAAgenotype was significantly higher in good responders (P 5 0.049). This genotype related response was even more evident in the subgroups of non-smokers (P 50.008) and in non-atopic patients (P 5 0.009). AA genotype was overrepresented among good responders according to changes in FEV1 in the subgroups of non-smokers (P 50.013) and in non-atopic patients (P 5 0.048). Our results showed that treatment response to ICS, assessed as changes in BHR and FEV1, is associated with TBX21


Related Articles

  • Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: a pilot study. Turton, James A.; Glasgow, Nicholas J.; Brannan, John D. // Primary Care Respiratory Journal;Mar2012, Vol. 21 Issue 1, p28 

    Aims: To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care. Methods: Fourteen adult patients with asthma aged 22-70 years (4M:10F, forced expiratory volume in 1 s >70%...

  • Relationship of Mannitol Challenge to Methacholine Challenge and Inflammatory Markers in Persistent Asthmatics Receiving Inhaled Corticosteroids. Anderson, William; Lipworth, Brian // Lung;Oct2012, Vol. 190 Issue 5, p513 

    Background: Mannitol is a novel osmotic indirect bronchial challenge agent used to aid asthma diagnosis and management and is thought to reflect underlying inflammatory processes in asthma. Our objective was to evaluate relationships between mannitol airway hyperresponsiveness (AHR) and other...

  • Chapter 15: Lessons learned from clinical trials of asthma. Sabin, Bradley R.; Avila, Pedro C.; Grammer, Leslie C.; Greenberger, Paul A. // Allergy & Asthma Proceedings;May/Jun2012 Supplement, Vol. 33, p51 

    The preponderance of clinical data suggest that inhaled corticosteroids (ICSs) are the preferred therapy for the long-term management of asthma, whereas oral or parental corticosteroids and short-acting beta2-adrenergic agonists remain the mainstay treatment of acute exacerbations. Allergen and...

  • Does Mild Persistent Asthma Require Regular Treatment? Fabbri, Leonardo M. // New England Journal of Medicine;4/14/2005, Vol. 352 Issue 15, p1589 

    Discusses the treatment of mild persistent asthma. Claim that established guidelines require regular treatment of mild persistent asthma with inhaled corticosteroids; Reference to a study which compared treatment methods; Focus of the study on self-management of mild persistent asthma; Benefits...

  • Budesonide/formoterol pressurized metered-dose inhaler: a guide to its use in asthma.  // Drugs & Therapy Perspectives;Nov2009, Vol. 25 Issue 11, p1 

    The corticosteroid budesonide and the long-acting β2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI). The combination pMDI improves lung function, asthma control, asthma symptoms and asthma-related quality of life outcomes in patients...

  • LABA dangers highlighted. Cameron, Amanda // New Zealand Doctor;8/9/2006, p6 

    The article discusses research being done on long-acting beta agonists (LABA) to treat asthma patients. It references a study by Shelley Salpeter et al, published in the 2006 issue of the "Annals of Internal Medicine." Clarification of the use of LABA in combination with inhaled corticosteroid...

  • Fighting the Constant Battle to Breathe. Esposito, Lisa // U.S. News Digital Weekly;9/12/2014, Vol. 6 Issue 37, p21 

    The article discusses the health issues confronted by asthma sufferers in the U.S. and their possible solutions. It claims that there are almost 19 million American adults who suffer asthma and that the gold standard of asthma treatment is the inhaled corticosteroid. American College of Allergy,...

  • Pharmacological evaluation of calendula officinalis L. on bronchial asthma in various experimental animals. Sagar, Rakesh; Bhusan Sahoo, Himanshu; Kar, Biswakanth; Kishor Mishra, Nikunja; Mohapatra, Rajaram; Prasad Sarangi, Sarada // International Journal of Nutrition, Pharmacology, Neurological D;Apr2014, Vol. 4 Issue 2, p95 

    Background: Calendula officinalis Linn. (Asteraceae) is an aromatic herb growing in the forests of India, China, Central Europe, and some tropical areas. The study was designed to investigate the scientific basis for the traditional claim of C. Officinalis on asthma. In the present study,...

  • Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment. Sovij''rvi A R A; Haahtela T; Ekroos H J; Lindqvist A; Saarinen A; Poussa T; Laitinen L A // Thorax;Jun2003, Vol. 58 Issue 6, p500 

    BACKGROUND: Bronchial hyperresponsiveness (BHR) is characteristic of asthmatic airways, is induced by airway inflammation, and is reduced by inhaled corticosteroids (ICS). The time course for the onset and cessation of the effect of ICS on BHR is unclear. The effect of inhaled fluticasone...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics